Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

03-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: TNF inhibitors linked to reduced VTE risk in RA patients

Anja Strangfeld discusses an analysis of the German RABBIT registry comparing the risk for venous thromboembolism among patients with rheumatoid arthritis treated with different classes of medication (5:20).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read the transcript

Related content

04-06-2020 | EULAR 2020 | Conference coverage | News

​​​​​​​TNF inhibitors linked to reduced VTE risk in RA patients

17-10-2019 | Rheumatoid arthritis | News

Treatment switching associated with VTE risk in RA

21-08-2019 | Tofacitinib | Feature | Article

Tofacitinib black box warning: A cause for concern?
How FDA alert about pulmonary embolism will affect rheumatoid arthritis treatment decisions

04-11-2019 | Tofacitinib | News

EMA issues updated advice on VTE risk with tofacitinib
Image Credits